Investment area
Seed Investments
Region
Europe
Date of investment
May 2016
NMD Pharma is developing novel treatments for Neuromuscular diseases such as Myasthenia gravis and ALS. The company is in preclinical development.
Contact
João Ribas
Principal
Department: Seed Investments
João Ribas joined Seed Investments in 2018, focusing on early-stage investments and venture creation. He currently holds several board positions and has led investments in companies like Asgard Therapeutics, Tribune Therapeutics, and Orbis Medicines. João often combines his investment role with interim operational responsibilities in portfolio companies.
Prior to Novo Holdings, he was a Fellow at M Ventures (corporate VC of Merck KGaA), involved in the entire investment process including deal sourcing, investment selection, and due diligence. Before this, João founded new ventures in the U.S. and Europe, earning several entrepreneurial awards. During his Ph.D., he was part of MIT Hacking Medicine and led a non-profit organization in the U.S.
João earned his Ph.D. from the University of Coimbra, conducting research at Harvard Medical School and Brigham and Women’s Hospital. He regularly creates content on biotech innovation, venture creation, and entrepreneurship.
